Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type: \6 l! {9 U6 |( y. S1 q$ B( E: D2 X. l
NOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9
j. M' X& q6 A% j: S5 u# U& Z+ Author Affiliations1 Z6 b A0 t, J8 p9 b% [5 G
9 | p: ]# O; _$ q' A1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan # }4 z' h* `. Y2 x
2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
; I6 q" ~' p% _+ b% F& ^0 R" O$ {8 I3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
' s+ m$ @5 p9 L) D+ H4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan
% } l ?: y! }- N: }& A" l5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan & j. Y8 P+ H+ ~; x
6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan
( H7 ~7 e/ b- g% {+ M6 G, H7Kinki University School of Medicine, Osaka 589-8511, Japan
8 {3 H! i* |' J. r) S8Izumi Municipal Hospital, Osaka 594-0071, Japan & d; M" v+ q h% l4 N" i
9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan ) N$ J: D: y( N% y$ r) A
Correspondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp
5 b7 J8 L2 Q" A3 HAbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type.
8 J/ O2 C% I9 @. o7 U2 [: K) l! t
" y2 d1 C6 H) i R9 O$ s |